|
|
|
|
|
|
|
12.05.26 - 18:09
|
Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product ′Noise′: Analysts (Benzinga)
|
|
|
Hims & Hers Health shares tank after disappointing Q1 results. Company raised 2026 revenue outlook. EBITDA outlook was lowered by $25M.
Latest Ratings for HIMS
DateFirmActionFromTo Mar 2022Deutsche BankInitiates Coverage OnHold Dec 2021CitigroupMaintainsBuy Dec 2021JefferiesInitiates Coverage OnHold
View More Analyst Ratings for HIMS
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
12.05.26 - 18:06
|
Under Armour Slides on Guidance Miss; Wendy′s Up on Private Operator Bid | Stock Movers (Bloomberg)
|
|
|
On this episode of Stock Movers with Alexis Christoforous:
- Under Armour (UAA) shares are sliding after it forecast adjusted earnings per share for 2027 and the guidance missed the average analyst estimate.
- Wendy's (WEN) shares are gaining as Financial Times reports that Nelson Peltz's Trian Fund Management is seeking investor backing for a bid to take the burger chain operator private.
- Hims & Hers (HIMS) shares are lower after reporting a first-quarter loss and sales that missed Wall Street estimates due to higher costs associated with its strategic pivot to branded weight-loss medications. (Source: Bloomberg)...
|
|
|
|
|
12.05.26 - 17:24
|
JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story (24/7 Wall St.)
|
|
|
Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target to $33 from $35 while reaffirming an Overweight rating, characterizing results as mixed and updating the 2026 outlook to reflect the strategic shift ... JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story...
|
|
|
12.05.26 - 14:33
|
HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook (ZeroHedge)
|
|
|
HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook
Hims & Hers shares tumbled in premarket trading in New York, the most in three months, after the company posted a first-quarter loss and revenue that missed analyst estimates tracked by Bloomberg, as costs rose amid a massive pivot from selling copycat GLP-1 drugs toward branded obesity drugs from Novo Nordisk and Eli Lilly.
Revenue for the first quarter came in at $608 million versus the $617.5 million Bloomberg Consensus estimate, while the telehealth firm swung to a loss of 40 cents a share from a 20-cent profit a year earlier.
HIMS recorded $33.5 million in restructuring charges, including inventory write-downs and transition costs.
"This was an incredibly valuable transition," HIMS CEO Andrew Dudum told analysts on an earnings call. "We are seeing adoption and weight-loss near-record levels, even beyond the demand we saw following this year's New Year's and Super Bowl campaigns."
Here's a snapshot o...
|
|
|
|
|
|
|
|
|
|
|
12.05.26 - 13:06
|
Hims & Hers: Aktie geht baden – die Hintergründe (Der Aktionaer)
|
|
|
Enttäuschung bei den Aktionären von Hims & Hers. Der amerikanische Betreiber einer Telehealth-Plattform hat mit den Zahlen zum ersten Quartal am Montag nach US-Börsenschluss für Ernüchterung gesorgt. Die Aktie verliert nach der Bilanzvorlage prozentual zweistellig an Wert....
|
|
|
12.05.26 - 12:45
|
Hims & Hers-Aktie erreicht wichtige Unterstützung für Turnaround (Sharedeals)
|
|
|
Die Aktie von Hims & Hers steht nach den neuen Quartalszahlen deutlich unter Druck. Obwohl das Unternehmen weiterhin wächst, reagiert die Aktie vorbörslich mit einem Minus von rund -15% und fällt damit zurück an eine wichtige Unterstützungszone. Hims & Hers enttäuscht bei Umsatz und Gewinn Die neuen Quartalszahlen von Hims & Hers kamen insgesamt schwächer […]
The post Hims & Hers-Aktie erreicht wichtige Unterstützung für Turnaround first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
